Pharmacodynamics effect of nerve growth factor-loaded nanoparticles to induce PC12 cells

doi:10.3969/j.issn.2095-4344.2013.16.006

Abstract

Abstract:

BACKGROUND: It is found that the surface-modified polymer nanoparticles can pass through the blood-brain barrier, and improve the drug effects on the central nervous system diseases.
OBJECTIVE: To prepare nerve growth factor-loaded high encapsulation efficiency nanoparticles with a iodegradable material, polyethylene glycol-polylactic acid glycolic acid copolymer, and to explore its effect on PC12 cells.
METHODS: Bovine serum albumin-loaded polyethylene glycol-polylactic acid glycolic acid copolymer nanoparticles were prepared using complex emulsion solvent diffusion method. The production process was screened by univariate analysis and orthogonal design method. The nanoparticle morphology was observed under scanning electron microscopy, and the average particle diameter and the dispersion index were measured by nanoparticle analyzer. The nanoparticle encapsulation efficiency and drug loading were analyzed by BCA method. Nanoparticle release in vitro was also investigated. After optimization of the preparation program, nerve growth factor-loaded polymer nanoparticles were prepared and applied to PC12 cells. The cells were then observed by inverted fluorescence microscope, and the induction effects, toxicity and slow-release effect of polyethylene glycol-polylactic acid glycolic acid copolymer nanoparticles loaded with nerve growth factor were evaluated.
RESULTS AND CONCLUSION: Bovine serum albumin-loaded polyethylene glycol-polylactic acid glycolic acid copolymer nanoparticles were prepared by optimal method. The nanoparticles were spherical, and uniform in size, with an average particle size of (258.9±5.73) nm, and the encapsulation efficiency was (80.56±2.23)%. When the dosage within the aqueous phase was 10 mg, the drug loading was (4.24±0.12)%. The in vitro release of nanoparticles was in accordance with the Higuchi equation of. Release of the nanoparticles could be divided into two stages: initial burst release stage and late sustained release. The total cumulative release amount of bovine serum albumin and nerve growth factor in 0-56 days was 76.61% and 62.34%, respectively. The PC12 cells could be induced to differentiation by polyethylene glycol-polylactic acid glycolic acid copolymer nanoparticles loaded with nerve growth factor, and the nanoparticles exhibited good release properties and no toxic effects. It was showed that nerve growth factor-loaded polyethylene glycol-polylactic acid glycolic acid copolymer nanoparticles prepared by the optimal method had excellent physicochemical properties, good release properties in vitro and no toxic effects.

Key words: biomaterials, nanobiomaterials, nerve growth factor, polyethylene glycol-polylactic acid glycolic acid copolymer, nano-drugs, complex emulsion solvent diffusion method, nanoparticles, PC12 cells, provincial grants-supported paper

CLC Number:

R318

Bao Guo-qing, Long Da-hong, Chen Yan, Liu Fei-fei, Zhang Jun-du. Pharmacodynamics effect of nerve growth factor-loaded nanoparticles to induce PC12 cells[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(16): 2891-2898.

Figures/Tables 7

References

[1]Kirkland RA, Saavedra GM, Franklin JL. Rapid activation of antioxidant defenses by nerve growth factor suppresses reactive oxygen species during neuronal apoptosis: evidence for a role in cytochrome c redistribution. J Neurosci. 2007; 27(42):11315-11326.

[2]Colafrancesco V, Villoslada P. Targeting NGF pathway for developing neuroprotective therapies for multiple sclerosis and other neurological diseases. Arch Ital Biol. 2011;149(2):183-192.

[3]Shi ED, Wang BC, Sun QS. Nerve growth factor and injured peripheral nerve regeneration. Neural Negen Res 2008;3(11): 1273-1276 .

[4]Urbaniak A. p75NTR receptor--role in cell growth and apoptosis. Postepy Hig Med Dosw (Online). 2012;66:304-310.

[5]Allen SJ, Watson JJ, Dawbarn D. The neurotrophins and their role in Alzheimer's disease. Curr Neuropharmacol. 2011;9(4): 559-573.

[6]Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry. 2006;21(1): 17-28.

[7]Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008; 60(2): 196-209.

[8]Akhlaghi SP, Saremi S, Ostad SN, et al. Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines. Nanomedicine. 2010;6(5):689-697.

[9]Xu F, Lu W, Wu H, et al. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. J Drug Target. 2009;17(6):423-434.

[10]Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov Today. 2008;13 (23-24):1099-1106.

[11]Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials. 2010;31(8):2278-2292.

[12]Lemoine D, Francois C, Kedzierewicz F, et al. Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials. 1996;17(22):2191-2197.

[13]Hu S, Zhang Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation. Int J Nanomedicine. 2010;5: 1039-1048.

[14]Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290(1-2):137-144.

[15]Xie S, Wang S, Zhao B, et al. Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2008;67(2): 199-204.

[16]Mei L, Long DH, Huang WD. Jiepo Xue Yanjiu. 2010;32(1): 1-5. 梅林,龙大宏,黄婉丹,等.载牛血清蛋白的PLGA纳米粒制备工艺的优化及特性研究[J].解剖学研究.2010;32(1):1-5.

[17]Liu FF,Long DH. Jiepo Xue Yanjiu. 2011;33(2):95-100.刘菲菲,龙大宏.阳离子载基因Me PEG-PLGA纳米粒的制备及优化处方的筛选[J].解剖学研究.2011;33(2):95-100.

[18]Clavreul A, Sindji L, Aubert-Pouëssel A, et al. Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. Eur J Pharm Biopharm. 2006;63(2):221-228.

[19]Duan Y, Xu J, Lin Y, et al. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers. J Biomed Mater Res A. 2008;87(2):515-523.

[20]Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm. 2009; 6(1):173-181.

[21]Xu HB. Beijing: Tsinghua University Press, 2004. 徐辉碧.纳米医药[M].北京:清华大学出版社,2004.

[22]Yang A, Yang L, Liu W, et al. Tumor necrosis factor alpha blocking peptide loaded PEG-PLGA nanoparticles: preparation and in vitro evaluation. Int J Pharm. 2007;331 (1):123-132.